I. Expression across cell types
Name | Number of supported studies  | Average coverage | |
|---|---|---|---|
| endothelial cell | 38 studies | 31% ± 14% | |
| endothelial cell of lymphatic vessel | 16 studies | 36% ± 16% | |
| natural killer cell | 12 studies | 28% ± 18% | |
| endothelial cell of vascular tree | 12 studies | 29% ± 21% | |
| capillary endothelial cell | 11 studies | 27% ± 9% | |
| CD16-positive, CD56-dim natural killer cell, human | 8 studies | 24% ± 8% | |
| vein endothelial cell | 8 studies | 27% ± 14% | |
| endothelial cell of artery | 7 studies | 21% ± 5% | |
| basal cell | 7 studies | 35% ± 23% | |
| epithelial cell | 6 studies | 36% ± 14% | |
| CD16-negative, CD56-bright natural killer cell, human | 6 studies | 21% ± 4% | |
| astrocyte | 5 studies | 25% ± 9% | |
| lymphocyte | 4 studies | 26% ± 6% | |
| fibroblast | 4 studies | 37% ± 29% | |
| pericyte | 4 studies | 39% ± 30% | |
| goblet cell | 4 studies | 25% ± 14% | |
| glomerular endothelial cell | 3 studies | 19% ± 2% | |
| ciliated cell | 3 studies | 27% ± 3% | |
| GABAergic neuron | 3 studies | 20% ± 3% | |
| oligodendrocyte precursor cell | 3 studies | 21% ± 4% | |
| transit amplifying cell | 3 studies | 28% ± 14% | |
| oligodendrocyte | 3 studies | 20% ± 4% |
